Pfizer, Inc. with price, financials, news flow, and insider context in one page.
Pfizer, Inc. is being tracked here through price action, operating context, and headline flow. This public page covers the latest market move, where PFE sits inside Healthcare and Drug Manufacturers - General, and the key financial markers that matter before moving into a fuller research workflow.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
This page is structured for research context, not a trade call. It gives you a clean read on where PFE sits in its range, what the last few quarters look like, and which headlines are shaping attention.
For position sizing, alerts, saved watchlists, and deeper analysis workflows, the next step is the logged-in Meridian workspace.
| Quarter | Revenue | Net income | Free cash flow |
|---|---|---|---|
| Q1 2026 | 14.45B | 2.69B | 2.18B |
| Q4 2025 | 17.56B | -1.65B | 4.5B |
| Q3 2025 | 16.65B | 3.54B | 4B |
| Q2 2025 | 14.65B | 2.91B | -1.2B |
The attacks come as the United States and Iran are supposed to be engaging in a 60-day ceasefire as they attempt to work toward a resolution.
See the next report date, earnings cadence, and reporting context.
Open a side-by-side comparison page to frame valuation and growth.
Read open desk notes tied to sectors, macro themes, and active names.
Learn the framework behind valuation, momentum, and risk before you act.
Pfizer, Inc. (PFE) — questions investors ask
What is the current stock price of Pfizer, Inc. (PFE)?
Pfizer, Inc. (PFE) is trading at $24.29, up 2.62% in the latest session. The live price and one-year chart on this page update through the trading day.
What is Pfizer, Inc.'s market capitalization?
Pfizer, Inc. has a market capitalization of about 138.44B, derived from the latest share price and shares outstanding.
When is Pfizer, Inc.'s next earnings date?
Pfizer, Inc. is next expected to report earnings on Aug 4, 2026. The PFE earnings page tracks the estimate and reporting history.
What is Pfizer, Inc.'s P/E ratio?
Pfizer, Inc. trades at a forward price-to-earnings ratio of 8.59 — one measure of how the market is pricing its future earnings.
What is PFE's 52-week trading range?
Over the past 52 weeks, PFE has traded between $23.11 and $28.75.
What sector is Pfizer, Inc. in?
Pfizer, Inc. operates in the Healthcare sector, within the Drug Manufacturers - General industry.
Does Pfizer, Inc. pay a dividend?
Pfizer, Inc. currently carries a dividend yield of about 100.0%.
What is the analyst price target for PFE?
The mean analyst price target for PFE is $29.15, with an overall analyst view of Buy.
A public stock page should answer the first research questions before asking for a signup.
This PFE page is designed for public research utility. You can read the latest session move, check the one-year chart, review a compact financial table, scan recent headlines, and compare adjacent names without immediately moving into a gated dashboard.
The logged-in Meridian workflow goes further with saved watchlists, deeper analysis, alert routing, and recurring review systems. The public layer is meant to be credible and indexable on its own, not a hollow teaser page.